BiotechTube

SDP-133 + Lumigan

Phase 3Withdrawn
0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Open Angle Glaucoma

Conditions

Open Angle Glaucoma, Ocular Hypertension

Trial Timeline

Jun 10, 2019 → Jul 8, 2019

NCT ID
NCT03927443

About SDP-133 + Lumigan

SDP-133 + Lumigan is a phase 3 stage product being developed by Sun Pharmaceutical for Open Angle Glaucoma. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT03927443. Target conditions include Open Angle Glaucoma, Ocular Hypertension.

What happened to similar drugs?

20 of 20 similar drugs in Open Angle Glaucoma were approved

Approved (20) Terminated (4) Active (0)
✅Latanoprost plus adjunctive glaucoma medicationSight SciencesApproved
✅MicafunginAstellas PharmaApproved
✅Teriparatide + Zoledronic AcidEli LillyApproved
✅alendronate sodiumMerckApproved
✅Imipenem + ImipenemMerckApproved
✅Ceftolozane-Tazobactam + MeropenemMerckApproved
✅Ceftolozane-tazobactam IVMerckApproved

Hype Score Breakdown

Clinical
17
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03927443Phase 3Withdrawn

Competing Products

20 competing products in Open Angle Glaucoma

See all competitors
ProductCompanyStageHype Score
Ilofotase alfa + PlaceboAM-PharmaPhase 2
25
Test - Bimatoprost 0.01% Ophthalmic Solution + Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution)Mankind PharmaPhase 3
40
Latanoprost plus adjunctive glaucoma medicationSight SciencesApproved
25
Pirtobrutinib + PlaceboEli LillyPhase 1/2
39
Anti-(integrin beta-3) human monoclonal antibodyRallybioPhase 2
17
SBI-100 Ophthalmic Emulsion, 0.5% + SBI-100 Ophthalmic Emulsion, 1.0% + SBI-100 Ophthalmic Emulsion, PlaceboSkye BiosciencePhase 2
25
MicafunginAstellas PharmaApproved
39
Brinzolamide ophthalmic suspension + Azopt®Sun PharmaceuticalPhase 3
40
Placebo + LusutrombopagShionogiPhase 2
27
LusutrombopagShionogiPhase 2
27
Avatrombopag + Avatrombopag + PlaceboEisaiPhase 2
35
E5501EisaiPhase 1
29
avatrombopagEisaiPhase 1
29
E5501 + Drug: E5501EisaiPhase 1
29
E5501 40 mg 2 x 20-mg tablets, orally, fasted + E5501 40 mg 2 x 20-mg tablets, orally, with food + E5501 40mg 2 x 20-mg tablets, orally, fasted + E5501 40 mg 2 x 20-mg tablets, orally, with foodEisaiPhase 1
29
Eltrombopag + Avatrombopag + Standard of careEisaiPhase 3
32
Placebo + Avatrombopag tabletsEisaiPhase 2
35
avatrombopag (lower baseline platelet count) + placebo (lower baseline platelet count) + avatrombopag (higher baseline platelet count) + placebo (higher baseline platelet count)EisaiPhase 3
40
avatrombopag + PlaceboEisaiPhase 2
35
Avatrombopag + Placebo + Pegylated interferon (PEG-IFN) + Telaprevir + RibavirinEisaiPhase 2
35